{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Kiniksa Pharmaceuticals International Plc
Kiniksa Pharmaceuticals Hits New 52-Week High of USD 49.12
Kiniksa Pharmaceuticals International Plc has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has shown impressive growth over the past year, with significant increases in operating profit, cash flow, and net sales, alongside robust institutional ownership.
Kiniksa Pharmaceuticals: A Multibagger with 140.68% Return and Strong Financial Metrics
Kiniksa Pharmaceuticals International Plc has recently undergone a revision in its score, reflecting its strong operational performance and market position. The company reported significant growth in operating profit and net sales, alongside a solid financial foundation, making it an attractive option for investors in the pharmaceuticals sector.
Kiniksa Pharmaceuticals Hits New 52-Week High of $39.60
Kiniksa Pharmaceuticals International Plc achieved a new 52-week high of USD 39.60 on October 24, 2025, highlighting its strong performance in the pharmaceuticals sector. The company reported a 44.61% return over the past year and impressive financial metrics, indicating solid operational health and growth potential.
Kiniksa Pharmaceuticals Hits New 52-Week High of USD 39.12
Kiniksa Pharmaceuticals International Plc achieved a new 52-week high of USD 39.12 on October 1, 2025, reflecting strong performance in the pharmaceuticals sector. The company reported a 54.56% return over the past year, significant net profit growth, and a solid balance sheet, showcasing its resilience in a competitive market.
Kiniksa Pharmaceuticals Hits New 52-Week High of $38.97
Kiniksa Pharmaceuticals International Plc achieved a new 52-week high of USD 38.97 on September 30, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company reported a 52.30% return over the past year and impressive net profit growth of 108.83%, highlighting its operational strength.
Is Kiniksa Pharmaceuticals International Plc technically bullish or bearish?
As of October 1, 2023, Kiniksa Pharmaceuticals is in a bullish technical position, with positive indicators across multiple time frames, and has significantly outperformed the S&P 500 year-to-date with an 81.60% return compared to 12.22%.
Is Kiniksa Pharmaceuticals International Plc overvalued or undervalued?
As of August 11, 2025, Kiniksa Pharmaceuticals International Plc's valuation has shifted from fair to attractive, indicating it may be undervalued despite a high P/E ratio of 565.79 and an EV to EBITDA ratio of 402.35, while outperforming the S&P 500 with an 81.60% year-to-date return.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
